Pervasis Therapeutics

edit

Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Milestones

edit

• 
  Pervasis Therapeutics received $17.4M in Series C funding. (8/31/09)
  Posted 9/24/09 at 3:17pm

Videos

Screenshots

edit

Above: Pervasis Therapeutics
Uploaded: 10/16/09

Sources

1. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member (news.prnewswire.com) [edit]